Zymeworks reports Phase 1 data for ZW191 showing high response rates and better tolerability at 6.4 mg/kg
Zymeworks Inc. presented new Phase 1 results for its folate‑receptor‑α‑targeting ADC ZW191 at the ESMO Congress 2026. In 80 heavily pre‑treated platinum‑resistant ovarian cancer patients, the 6.4 mg/kg dose achieved a confirmed objective response rate of 64.5% and a six‑month progression‑free survival of 61%, with a more favorable safety profile than the 9.6 mg/kg dose. The company will discuss the data on a conference call on 27 October 2026 and is seeking strategic partnership opportunities to fund further development.
Why it matters
Zymeworks says the strong efficacy and tolerability at the lower dose support continued clinical development and justify pursuing strategic collaborations, which could provide additional funding and accelerate the program. The data may improve investor sentiment toward the company’s pipeline.
Key facts
- 1The Phase 1 dose‑optimization study enrolled 80 patients with platinum‑resistant ovarian cancer, randomized to 6.4 mg/kg (n=37) or 9.6 mg/kg (n=43). stocktitan.net
- 2At the 6.4 mg/kg dose, the confirmed objective response rate (cORR) was 64.5%. thewhig.com
- 3At the 9.6 mg/kg dose, the cORR was 55.3%. finanznachrichten.de
- 4Six‑month progression‑free survival was 61% in both dose groups. thewhig.com
- 5Grade 3 or higher treatment‑related adverse events occurred in 22% of patients at 6.4 mg/kg versus 44% at 9.6 mg/kg. finanznachrichten.de
- 6A conference call to discuss the results is scheduled for 27 October 2026 at 8:30 am Eastern Time. stocktitan.net
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.